Zhao Yuyang, Wang Jiangbin, Sun He
Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
School of Management Science and Information Engineering, Jilin University of Finance and Economics, Changchun, Jilin, China.
Front Med (Lausanne). 2025 Jul 16;12:1517462. doi: 10.3389/fmed.2025.1517462. eCollection 2025.
Recent studies suggest that individuals with inflammatory bowel disease (IBD) are at a significantly higher risk of developing non-alcoholic fatty liver disease (NAFLD) compared to the general populace. Furthermore, the coexistence of NAFLD is likely to intensify the overall health impact experienced by individuals with IBD.
This review aims to assess the prevalence of NAFLD and its associated risk factors in IBD patients through systematic analysis. We searched for relevant literature in the PubMed and Medline databases from January 2014 to April 2024 and conducted a meta-analysis to quantitatively synthesize eligible studies, the search criteria were designed to encompass a broad spectrum of research investigating the link between IBD and NAFLD. After completing the literature search, a meticulous screening process was undertaken to filter out studies that did not meet the predefined eligibility criteria.
The analysis encompassed 26 studies, representing a cohort of over 429,550 IBD patients. Our study indicated that the aggregate incidence of NAFLD within this IBD population was 34%, with a 95% confidence interval ranging from 27% to 41%. Additionally, the research highlighted that the likelihood of NAFLD onset is increased in IBD patients with a prolonged illness duration, obesity, and those presenting metabolic syndrome characteristics.
The incidence of NAFLD among individuals with IBD notably exceeds that observed in the general populace. This heightened prevalence correlates with factors such as disease severity, metabolic risk profiles, and the impact of pharmacological interventions. Further research is needed to further elucidate these risk factors and establish screening recommendations.
近期研究表明，与普通人群相比，炎症性肠病（IBD）患者患非酒精性脂肪性肝病（NAFLD）的风险显著更高。此外，NAFLD的共存可能会加剧IBD患者所经历的整体健康影响。
本综述旨在通过系统分析评估IBD患者中NAFLD的患病率及其相关危险因素。我们在2014年1月至2024年4月期间在PubMed和Medline数据库中搜索了相关文献，并进行了荟萃分析以定量综合符合条件的研究，搜索标准旨在涵盖广泛的研究IBD与NAFLD之间联系的研究。完成文献搜索后，进行了细致的筛选过程，以排除不符合预定义纳入标准的研究。
该分析涵盖了26项研究，代表了超过429,550名IBD患者的队列。我们的研究表明，该IBD人群中NAFLD的总发病率为34%，95%置信区间为27%至41%。此外，研究强调，病程延长、肥胖以及具有代谢综合征特征的IBD患者发生NAFLD的可能性增加。
IBD患者中NAFLD的发病率明显高于普通人群。这种较高的患病率与疾病严重程度、代谢风险状况以及药物干预的影响等因素相关。需要进一步研究以进一步阐明这些危险因素并制定筛查建议。
